Animal Study Suggests Acetaminophen May Protect Against Colon Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 5
Volume 9
Issue 5

SAN FRANCISCO-Research conducted at New York Medical College, Valhalla, shows that acetaminophen may prevent early biologic changes that can lead to colon cancer.

SAN FRANCISCO—Research conducted at New York Medical College, Valhalla, shows that acetaminophen may prevent early biologic changes that can lead to colon cancer.

In the study, presented at the American Association for Cancer Research (AACR) annual meeting, rats were given low or high doses of 3,2´dimethyl-4-aminobiphenyl (DMAB), a chemical that mimics suspected human colon carcinogens (heterocyclic amines formed during cooking of protein), and acetaminophen or no acetaminophen.

In the animals given carcinogen alone, cellular changes that are common precursors to colon cancer were seen, in relationship to the dose. When the carcinogen was given after acetaminophen, the animals had significantly less cellular evidence of disease, especially gland cell hypertrophy and karyomegaly.

“In our study, even low levels of acetaminophen showed a powerful protective effect in colon cells exposed to DMAB,” said Gary M. Williams, MD, professor of pathology, New York Medical College, at an AACR poster session. “We noted these effects even in animals exposed to much higher doses of DMAB than a human would ever encounter.”

The study was funded in part by a research grant from McNeil Consumer Healthcare.

Related Videos
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
The toxicity profile of tislelizumab also appears to look better compared with chemotherapy in metastatic esophageal squamous cell carcinoma.
Patients with unresectable or metastatic esophageal squamous cell carcinoma and higher PD-L1 expression may benefit from treatment with tislelizumab, according to Syma Iqbal, MD.
Quantifying disease volume to help identify potential recurrence following surgery may be a helpful advance, according to Sean Dineen, MD.
Tanios S. Bekaii-Saab, MD, and the Oncology Brothers presenting slides
Tanios S. Bekaii-Saab, MD, and the Oncology Brothers presenting slides
Tanios S. Bekaii-Saab, MD, and the Oncology Brothers presenting slides
Tanios S. Bekaii-Saab, MD, and the Oncology Brothers presenting slides
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.